A new type I IFN-mediated pathway for the rapid differentiation of monocytes into highly active dendritic cells

Stem Cells

Volumn 21, Issue 3, 2003, Pages 357-362

  Santini, S M ^a   Di Pucchio, T ^a   Lapenta, C ^a   Parlato, S ^a   Logozzi, M ^a   Belardelli, F ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

APC; Dendritic cells; Type I IFN; Vaccines

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON;

ANTIGEN PRESENTING CELL; CELL DIFFERENTIATION; CELL SUBPOPULATION; CONFERENCE PAPER; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; LEUKOCYTE; MONOCYTE;

EID: 0038526310     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.21-3-357     Document Type: Conference Paper

References (35)

1. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-3287.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
3. Bell D, Young JW, Banchereau J. Dendritic cells. Adv Immunol 1999;72:255-324.
4. Siegal FP, Kadowaki N, Shodell M et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-1837.
5. Cella M, Jarrossay D, Facchetti F et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999;5:919-923.
6. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-1118.
7. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
8. Thumher M, Zelle-Rieser C, Ramoner R et al. The disabled dendritic cell. FASEB J 2001;15:1054-1061.
9. Bogdan C. The function of type I interferons in antimicrobial immunity. Curr Opin Immunol 2000;12:419-424.
10. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995;103:161-179.
11. Le Bon A, Schiavoni G, D'Agostino G et al. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001;14:461-470.
12. Mattei F, Schiavoni G, Belardelli F et al. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol 2001;167:1179-1187.
13. Santini SM, Lapenta C, Logozzi M et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000;191:1777-1788.
14. Parlato S, Santini SM, Lapenta C et al. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 2001;98:3022-3029.
15. Jonuleit H, Wiedemann K, Muller G et al. Induction of IL-15 messenger RNA and protein in human blood-derived dendritic cells: a role for IL-15 in attraction of T cells. J Immunol 1997;158:2610-2615.
16. Vidalain PO, Azocar O, Yagita H et al. Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand. J Immunol 2001;167:3765-3772.
17. Liu S, Yu Y, Zhang M et al. The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J Immunol 2001;166:5407-5415.
18. Fanger NA, Maliszewski CR, Schooley K et al. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 1999;190:1155-1164.
19. Vidalain PO, Azocar O, Lamouille B et al. Measles virus induces functional TRAIL production by human dendritic cells. J Virol 2000;74:556-559.
20. Dieu-Nosjean MC, Vicari A, Lebecque S et al. Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. J Leukoc Biol 1999;66:252-262.
21. Sozzani S, Allavena P, Vecchi A et al. Chemokines and dendritic cell traffic. J Immunol 2000;20:151-160.
22. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000;18:593-620.
23. Mosier DE, Gulizia RJ, Baird SM et al. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988;335:256-259.
24. Mosier DE, Gulizia RJ, Baird SM et al. Human immunodeficiency virus infection of human-PBL-SCID mice. Science 1991;25:791-794.
25. Santini SM, Lapenta C, Logozzi M et al. Chimeric models of SCID mice transplanted with human cells: the Hu-PBL-SCID mouse and its use in AIDS research. In: Cossarizza A, Kaplan D, eds. Cellular Aspects of HIV Infection. New York: Wiley-Liss Inc., 2002:385-398.
26. Santini SM, Di Pucchio T, Lapenta C et al. The natural alliance between type I IFN and dendritic cells and its role in linking innate and adaptive immunity. J Interferon Cytokine Res 2002;22:1071-1080.
27. Mogensen KE, Lewerenz M, Reboul J et al. The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res 1999;19:1069-1098.
28. Cella M, Salio M, Sakakibara Y et al. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 1999;189:821-829.
29. + effector T cells. J Leukoc Biol 2002;71:669-676.
30. Ito T, Amakawa R, Inaba M et al. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol 2001;166:2961-2969.
31. Luft T, Luetjens P, Hochrein H et al. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol 2002;14:367-380.
32. Luft T, Pang KC, Thomas E et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998;161:1947-1953.
33. Gauzzi MC, Canini I, Eid P et al. Loss of type I IFN receptors and impaired IFN responsiveness during terminal maturation of monocyte-derived human dendritic cells. J Immunol 2002;169:3038-3045.
34. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001;94:459-473.
35. Brossart P, Wirths S, Brugger W et al. Dendritic cells in cancer vaccines. Exp Hematol 2001;29:1247-1255.